Efficacy is seen in adults as well, as evidenced in a phase II trial of crizotinib in 12 patients with R/R ALK-positive ALCL, in which the ORR was 84% with a 59% CR rate [90]. The gene discussed is ALK; the disease is anaplastic large cell lymphoma.